How Does Bexagliflozin (Brenzavvy) Work? Mechanism of Action Explained in Plain English

Bexagliflozin (Brenzavvy) works differently from most diabetes medications. It doesn't target the pancreas or insulin. Instead, it targets the kidneys — using a completely different approach to lower blood sugar. Here's exactly how it works, in plain English.

Understanding Blood Sugar and the Kidneys

Your kidneys filter your blood constantly — about 180 liters per day. As blood passes through the kidneys' tiny filtering units (called nephrons), glucose passes into the filtered fluid. Normally, almost all of that glucose gets reabsorbed back into the bloodstream — your body doesn't want to waste calories.

In type 2 diabetes, blood glucose is too high. Your kidneys filter extra glucose, but they also reabsorb that extra glucose — keeping blood sugar elevated. That's where bexagliflozin comes in.

What Is SGLT2 and What Does It Do?

SGLT2 stands for sodium-glucose co-transporter 2. It's a protein (transporter) located in the proximal convoluted tubule — the part of the kidney responsible for most glucose reabsorption. SGLT2 is responsible for about 90% of the glucose that gets reabsorbed back into your blood after kidney filtration.

Think of SGLT2 as a revolving door — glucose that passes through the kidney's filter tries to get back through this door into your bloodstream. In healthy people, this is fine. In people with type 2 diabetes and too much glucose, this door is making the problem worse by bringing all that excess sugar back in.

How Does Bexagliflozin Block SGLT2?

Bexagliflozin is a selective SGLT2 inhibitor. It binds to and blocks the SGLT2 transporter, preventing it from pulling glucose back into the bloodstream. The result: glucose that passes through the kidney filter continues into the urine and is excreted out of the body.

This is called glycosuria — glucose in the urine. Normally this would be a problem (it's a sign of uncontrolled diabetes), but in this case it's intentional and therapeutic. Your kidneys are releasing excess sugar on purpose, lowering your blood glucose in the process.

Why Does This Make You Urinate More?

When bexagliflozin blocks SGLT2, more glucose stays in the kidney filtrate. Glucose draws water with it through a process called osmosis. More glucose in urine = more water in urine = more frequent urination. This is expected and is part of how the drug works. Staying well-hydrated helps.

Additional Benefits Beyond Blood Sugar Control

Because bexagliflozin causes the body to excrete glucose (calories) in urine, it also has some secondary effects:

Modest weight loss — Excreting glucose means losing calories (~300–400 calories/day of sugar in the urine). In the BEST trial, patients lost about 6 pounds over 48 weeks.

Blood pressure reduction — Increased urination causes a reduction in blood volume, which modestly reduces systolic blood pressure (approximately 2–3 mmHg).

Kidney protection — Reducing pressure in the kidney's filtering units may reduce long-term kidney damage in diabetes. Bexagliflozin was the first SGLT2 inhibitor to demonstrate efficacy in patients with type 2 diabetes and stage 3 CKD.

Cardiovascular benefits (class effect) — CV outcomes data for bexagliflozin showed lower rates of HF hospitalization and all-cause mortality vs. placebo in a CV outcomes trial.

How Does Bexagliflozin Compare to Insulin and Metformin?

Unlike insulin, bexagliflozin does not directly affect insulin production or sensitivity. It simply removes glucose from the body. Unlike metformin, which works in the liver to reduce glucose production, bexagliflozin works in the kidneys.

Because it doesn't require working beta cells or intact insulin signaling, it can lower blood sugar even in advanced type 2 diabetes. It can be combined with metformin, insulin, DPP-4 inhibitors, sulfonylureas, or GLP-1 agonists.

How Long Does It Take for Bexagliflozin to Work?

Bexagliflozin starts working within 24 hours — you may notice increased urination on the first day. Meaningful blood sugar reductions (fasting glucose) can be seen within 1–2 weeks. The peak A1C-lowering effect is measured at 24 weeks and maintained for up to 3 years in clinical trials.

The drug has a half-life of approximately 12 hours and is primarily metabolized by UGT1A9 (an enzyme in the liver and kidneys), with minor involvement from CYP3A.

Understanding the mechanism also explains many of the side effects. For a complete list of side effects and precautions, see our guide on Brenzavvy side effects.

Ready to fill your Brenzavvy prescription? medfinder calls pharmacies near you to find which ones have it in stock.